N-(2-Hydroxypropyl)methacrylamide (HPMA) copolymer—drug conjugates bearing the antiinflammatory and anti-proliferative drug dexamethasone (DEX) and the anti-cancer drug doxorubicin (DOX) bound to either the polymer carrier separately or in combination, were synthesized. Both the in vitro and in vivo anti-cancer activity on mouse B-cell (38C13) and T-cell (EL4) lymphoma was studied. The conjugates were fairly stable in model buffers at pH 7.4, simulating blood pH, and the drug was released by chemical hydrolysis at pH values based on the endosomal and lysosomal environments in the target cells (pH 5—6). As a control, polymer conjugates containing only a single-drug (DOX or DEX) attached to the HPMA copolymer carrier were synthesized and tested. Contrary to the treatment with either single drug conjugate, where no significant long-term survival was observed, a synergistic effect of the two drugs was manifested in vivo. Treatment of mice bearing B-cell lymphoma 38C13 formulated as a mixture of both single drug-containing conjugates or a as a conjugate with both drugs in combination gave long-term survivors.
Peterson CM, Lu JM, Sun Y., et al. Combination chemotherapy and photodynamic therapy with N-(2- hydroxypropyl)methacrylamide copolymer-bound anticancer drugs inhibit human ovarian carcinoma heterotransplanted in nude mice. Cancer Res1996; 56(17): 3980-3985.
2.
Vicent MJ, Greco F., Nicholson RI, et al. Polymer therapeutics designed for a combination therapy of hormone-dependent cancer. Angew Chem Int Ed Engl2005; 44(26): 4061-4066.
3.
Alexanian R. , Dimopoulos MA, Delasalle K., et al. Primary dexamethasone treatment of multiple myeloma. Blood1992; 80(4): 887-890.
4.
Hussein MA, Wood L., Hsi E., et al. A phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients. Cancer2002; 95(10): 2160-2168.
5.
Oakervee HE, Popat R., Curry N., et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol2005; 129(6): 755-762.
6.
Tosi P., Zamagni E., Cellini C., et al. Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. Eur J Haematol2004; 73(2): 98-103.
7.
Garcia-Sanz R., Gonzalez-Lopez TJ, Vazquez L., et al. The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkin’s lymphoma. Eur J Haematol2010; 84(3): 266-270.
8.
Gozzetti A., Fabbri A., Oliva S., et al. Weekly bortezomib, pegylated liposomal doxorubicin, and dexamethasone is a safe and effective therapy for elderly patients with relapsed/refractory multiple myeloma. Clin Lymphoma Myeloma Leuk2010; 10(1): 68-72.
9.
Hussein MAModifications to therapy for multiple myeloma: pegylated liposomal doxorubicin in combination with vincristine, reduced-dose dexamethasone, and thalidomide . Oncologist2003; 8(Suppl. 3): 39-45.
10.
Lokhorst HM , Van Der Holt B., Zweegman S., et al. A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma . Blood2010; 115(6): 1113-1120.
11.
Offidani M. , Leoni P., Corvatta L., et al. ThaDD plus high dose therapy and autologous stem cell transplantation does not appear superior to ThaDD plus maintenance in elderly patients with de novo multiple myeloma. Eur J Haematol2010; 84(6): 474-483.
12.
Tsukune Y., Isobe Y., Yasuda H., et al. Activity and safety of combination chemotherapy with methotrexate, ifosfamide, L-asparaginase and dexamethasone (MILD) for refractory lymphoid malignancies: a pilot study. Eur J Haematol2010; 84(4): 310-315.
13.
Wang H., Li M., Rinehart JJ and Zhang R.Dexamethasone as a chemoprotectant in cancer chemotherapy: hematoprotective effects and altered pharmacokinetics and tissue distribution of carboplatin and gemcitabine. Cancer Chemother Pharmacol2004; 53(6): 459-467.
14.
Wang H., Li M., Rinehart JJ and Zhang R.Pretreatment with dexamethasone increases antitumor activity of carboplatin and gemcitabine in mice bearing human cancer xenografts: in vivo activity, pharmacokinetics, and clinical implications for cancer chemotherapy. Clin Cancer Res2004; 10(5): 1633-1644.
15.
Wang H., Wang Y., Rayburn ER, et al. Dexamethasone as a chemosensitizer for breast cancer chemotherapy: potentiation of the antitumor activity of adriamycin, modulation of cytokine expression, and pharmacokinetics. Int J Oncol2007; 30(4): 947-953.
16.
Duncan R. and Vicent MJDo HPMA copolymer conjugates have a future as clinically useful nanomedicines? A critical overview of current status and future opportunities. Adv Drug Deliv Rev2010; 62(2): 272-282.
17.
Ulbrich K. and Subr V.Structural and chemical aspects of HPMA copolymers as drug carriers. Adv Drug Deliv Rev2010; 62(2): 150-166.
18.
Kopeček J. and Kopečková P.HPMA copolymers: Origins, early developments, present, and future. Adv Drug Deliv Rev2010; 62(2): 122-149.
19.
Kopecek J., Kopecková P., Minko T. and Lu ZRHPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action. Eur J Pharm Biopharm2000; 50(1): 61-81.
20.
Říhová B. and Kovář M.Immunogenicity and immunomodulatory properties of HPMA-based polymers. Adv Drug Deliv Rev2010; 62(2): 184-191.
21.
Krakovičová H., Etrych T. and Ulbrich K.HPMA-based polymer conjugates with drug combination . Eur J Pharm Sci2009; 37: 405-412.
22.
Leinweber FJPossible physiological roles of carboxylic ester hydrolases. Drug Metab Rev1987; 18(4): 379-439.
23.
Li B., Sedlacek M., Manoharan I., et al. Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. Biochem Pharmacol2005; 70(11): 1673-1684.
24.
Ulbrich K., Šubr V., Strohalm J., et al. Polymeric drugs based on conjugates of synthetic and natural macromolecules I. Synthesis and physico-chemical characterisation. J Control Release2000; 64: 63-79.
25.
Etrych T., Mrkvan T., Chytil P., et al. N-(2-hydroxypropyl)methacrylamide-based polymer conjugates with pH-controlled activation of doxorubicin. I. New synthesis, physicochemical characterization and preliminary biological evaluation. J Appl Polym Sci2008; 109(5): 3050-3061.
26.
Říhová B., Etrych T., Pechar M., et al. Doxorubicin bound to a HPMA copolymer carrier through hydrazone bond is effective also in a cancer cell line with a limited content of lysosomes. J Control Release2001; 74: 225-232.
27.
Mrkvan T., Šírová M. , Etrych T., et al. Chemotherapy based on HPMA copolymer conjugates with pH-controlled release of doxorubicin triggers anti-tumor immunity . J Control Release2005; 110: 119-129.
28.
Etrych T., Jelínková M., Říhová B. and Ulbrich K.New HPMA copolymers containing doxorubicin bound via pH-sensitive linkage: synthesis and preliminary in vitro and in vivo biological properties. J Control Release2001; 73: 89-102.
29.
Etrych T., Chytil P., Jelínková M., et al. Synthesis of HPMA copolymers containing doxorubicin bound via a hydrazone linkage: effect of spacer on drug release and in vitro cytotoxicity . Macromol Biosci2002; 2(1): 43-52.
30.
Etrych T., Mrkvan T., Chytil P., et al. Polymer prodrugs based on HPMA conjugates with pH-controlled activation of doxorubicin: I. Synthesis, physicochemical characterisation and preliminary biological evaluation. Macromol Biosci2009; 37(3-4): 405-412.
31.
Etrych T., Šírová M. , Starovoytova L., et al. HPMA copolymer conjugates of paclitaxel and docetaxel with pH-controlled drug release. Mol Pharm2010; 7(4): 1015-1026.
32.
Sirova M., Strohalm J., Subr V., et al. Treatment with HPMA copolymer-based doxorubicin conjugate containing human immunoglobulin induces long-lasting systemic anti-tumour immunity in mice. Cancer Immunol Immunother2007; 56(1): 35-47.
